Top product, Humira, expected to keep growing through additional uses and an expanding pool of patients; Drug pipeline could provide topline growth in the longer term; and High dependence on a single product. Strong cash flow generation expected over the next two years; and Modest leverage. The rating outlook on AbbVie Inc. is positive, reflecting the potential that AbbVie will achieve sharp improvement in its credit measures by the end of 2014. Improved credit measures could lead us to revise our financial risk profile to minimal and provide support for an upgrade. We could raise the rating before the end of 2014 if we believe the company can sustain debt to EBITDA at less than 1.5x and funds from operations
